From Breakthrough to Backlash: Novo Nordisk's Ozempic Faces USD 2 Billion Lawsuit

Also Read: EMA flags rare vision risk with Semaglutide- a active substance in Ozempic, Rybelsus, Wegovy

MedPath reports that the legal fight began in August 2023, when the first patient alleged developing both stomach paralysis and vision impairment after using Ozempic. As similar complaints surfaced, the U.S. courts in February 2024 consolidated the cases into a multidistrict litigation (MDL) in the Eastern District of Pennsylvania, streamlining pretrial proceedings for the large pool of claimants. Legal analysts suggest that settlements or judgments could ultimately exceed the $2 billion mark, underscoring the vast scale of the potential liability.

As per the Business Standard report, the medical evidence cited in the litigation has added to the controversy. A 2023 study published in JAMA Internal Medicine found that users of GLP-1 drugs like Ozempic were at significantly higher risk of developing gastroparesis. Ophthalmologists have also reported abrupt and unexplained cases of vision loss correlating with recent Ozempic use. Meanwhile, the U.S. Food and Drug Administration’s adverse event database has recorded thousands of reports tied to gastrointestinal complications and sight-related problems.

Also Read: As Ozempic, Wegovy Take Priority, Novo Nordisk Winds Down Insulin Portfolio In India

Novo Nordisk, for its part, continues to defend the drug, asserting that Ozempic is safe when used as prescribed. The company emphasizes that warnings about gastrointestinal side effects are already included in its labeling. However, plaintiffs maintain that these disclosures fall short of fully reflecting the risks, particularly in the context of widespread prescriptions for weight loss, reports Financial Express.